Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 17:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a...
June 01, 2026 09:05 ET | Source: 24/7 Market News

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Eli Lilly's (NYSE:LLY) strong Phase 3 results for Retevmo places the oncology community in the spotlight
June 01, 2026 08:58 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant milestone in its pancreatic cancer development program,...
June 01, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
June 01, 2026 07:30 ET | Source: Immuneering Corporation

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
June 01, 2026 06:36 ET | Source: BCC Research LLC

Life Sciences Investment Opportunities Accelerate as AI and Genomics Drive $200+ Billion Market Expansion

The report tracks key market indicators, sustainability trends, investment flows and innovation patterns shaping the global life sciences landscape.
June 01, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
June 01, 2026 02:00 ET | Source: Curium

Curium Announces a Strategic Investment of Over €32 million in Saclay, France

Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate...
May 31, 2026 08:06 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
May 29, 2026 13:47 ET | Source: FDA

FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs

Silver Spring, Md., May 29, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for...